Organokines in COVID-19: A Systematic Review
Abstract
:1. Introduction
2. Materials and Methods
2.1. Focal Question
2.2. Language
2.3. Databases
2.4. Study Selection
2.5. Data Extraction
3. Discussion
3.1. Pathophysiology of the COVID-19 Infection
3.1.1. Inflammation, Immune Dysregulation, and Disease Progression
3.1.2. COVID-19 and Comorbidities
3.2. Adipokines in COVID-19
3.2.1. Adiponectin
3.2.2. Apelin
3.2.3. Leptin
3.2.4. Progranulin
3.3. Myokines in COVID-19
3.3.1. Irisin
3.3.2. Myostatin
3.3.3. Brain-Derived Neurotrophic Factor
3.4. Osteokines in COVID-19
Osteopontin
3.5. Hepatokines in COVID-19
3.5.1. Pentraxin 3
3.5.2. Fetuin-A
3.6. Cardiokines in COVID-19
3.6.1. Fibronectin Type III Domain Containing 5
3.6.2. Growth Differentiation Factor 15
3.7. Studies Evaluating the Role of Organokines in COVID-19 Patients
3.7.1. Miscellaneous
3.7.2. PTX3
3.7.3. PGRN
3.7.4. OPN
3.7.5. Adiponectin
3.7.6. Leptin
3.7.7. GDF15
3.7.8. Myostatin
3.7.9. BDNF
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Mo, W.; Wen, J.; Huang, J.; Yang, Y.; Zhou, M.; Ni, S.; Le, W.; Wei, L.; Qi, D.; Wang, S.; et al. Classification of Coronavirus Spike Proteins by Deep-Learning-Based Raman Spectroscopy and its Interpretative Analysis. J. Appl. Spectrosc. 2023, 89, 1203–1211. [Google Scholar] [CrossRef]
- He, J.; Zhu, S.; Zhou, J.; Jiang, W.; Yin, L.; Su, L.; Zhang, X.; Chen, Q.; Li, X. Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay. Front. Bioeng. Biotechnol. 2022, 10, 1090281. [Google Scholar] [CrossRef] [PubMed]
- Akkız, H. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern. Front. Med. 2022, 9, 849217. [Google Scholar] [CrossRef]
- Aiyegbusi, O.L.; Hughes, S.E.; Turner, G.; Rivera, S.C.; McMullan, C.; Chandan, J.S.; Haroon, S.; Price, G.; Davies, E.H.; Nirantharakumar, K.; et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021, 114, 428–442. [Google Scholar] [CrossRef] [PubMed]
- Gebeyehu, D.T.; East, L.; Wark, S.; Islam, M.S. Disability-adjusted life years (DALYs) based COVID-19 health impact assessment: A systematic review. BMC Public Health 2023, 23, 334. [Google Scholar] [CrossRef] [PubMed]
- Kadam, S.B.; Sukhramani, G.S.; Bishnoi, P.; Pable, A.A.; Barvkar, V.T. SARS-CoV-2, the pandemic coronavirus: Molecular and structural insights. J. Basic Microbiol. 2021, 61, 180–202. [Google Scholar] [CrossRef]
- Hu, B.; Guo, H.; Zhou, P.; Shi, Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [Google Scholar] [CrossRef] [PubMed]
- Barbalho, S.M.; Sloan, K.P.; Sloan, L.A.; Goulart, R.A.; Quesada, K.R.; Laurindo, L.F.; Zutin, T.L.M.; Bechara, M.D. Effects of Vitamin D in the Prophylaxis and Treatment of COVID-19: A Systematic Review. Med. Res. Arch. 2022, 10. [Google Scholar] [CrossRef]
- Suhail, S.; Zajac, J.; Fossum, C.; Lowater, H.; McCracken, C.; Severson, N.; Laatsch, B.; Narkiewicz-Jodko, A.; Johnson, B.; Liebau, J.; et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J. 2020, 39, 644–656. [Google Scholar] [CrossRef]
- Kim, J.S.; Lee, J.Y.; Yang, J.W.; Lee, K.H.; Effenberger, M.; Szpirt, W.; Kronbichler, A.; Shin, J.I. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 2021, 11, 316–329. [Google Scholar] [CrossRef]
- Jamal, M.; Bangash, H.I.; Habiba, M.; Lei, Y.; ** with Stress: The Mitokine GDF-15 as a Biomarker of COVID-19 Severity. Front. Immunol. 2022, 13, 820350. [Google Scholar] [CrossRef]
- Wischhusen, J.; Melero, I.; Fridman, W.H. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint. Front. Immunol. 2020, 11, 951. [Google Scholar] [CrossRef]
- Conte, M.; Ostan, R.; Fabbri, C.; Santoro, A.; Guidarelli, G.; Vitale, G.; Mari, D.; Sevini, F.; Capri, M.; Sandri, M. Human aging and longevity are characterized by high levels of mitokines. J. Gerontol. Ser. A 2019, 74, 600–607. [Google Scholar] [CrossRef]
- Wu, Q.; Jiang, D.; Schaefer, N.R.; Harmacek, L.; O’Connor, B.P.; Eling, T.E.; Eickelberg, O.; Chu, H.W. Overproduction of growth differentiation factor 15 promotes human rhinovirus infection and virus-induced inflammation in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2018, 314, L514–L527. [Google Scholar] [CrossRef] [PubMed]
- Teng, X.; Zhang, J.; Shi, Y.; Liu, Y.; Yang, Y.; He, J.; Luo, S.; Huang, Y.; Liu, Y.; Liu, D.; et al. Comprehensive Profiling of Inflammatory Factors Revealed That Growth Differentiation Factor-15 Is an Indicator of Disease Severity in COVID-19 Patients. Front. Immunol. 2021, 12, 662465. [Google Scholar] [CrossRef] [PubMed]
- Myhre, P.L.; Prebensen, C.; Strand, H.; Røysland, R.; Jonassen, C.M.; Rangberg, A.; Sørensen, V.; Søvik, S.; Røsjø, H.; Svensson, M.; et al. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19. Circulation 2020, 142, 2128–2137. [Google Scholar] [CrossRef] [PubMed]
- Fajgenbaum, D.C.; June, C.H. Cytokine Storm. N. Engl. J. Med. 2020, 383, 2255–2273. [Google Scholar] [CrossRef]
- Assandri, R.; Accordino, S.; Canetta, C.; Buscarini, E.; Scartabellati, A.; Tolassi, C.; Serana, F. Long pentraxin 3 as a marker of COVID-19 severity: Evidences and perspectives. Biochem. Med. 2022, 32, 020901. [Google Scholar] [CrossRef]
- Hansen, C.B.; Sandholdt, H.; Møller, M.E.E.; Pérez-Alós, L.; Pedersen, L.; Bastrup Israelsen, S.; Garred, P.; Benfield, T. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3. J. Innate Immun. 2022, 395, 493–501. [Google Scholar] [CrossRef]
- Brandes, F.; Borrmann, M.; Buschmann, D.; Meidert, A.S.; Reithmair, M.; Langkamp, M.; Pridzun, L.; Kirchner, B.; Billaud, J.N.; Amin, N.M.; et al. Progranulin signaling in sepsis, community-acquired bacterial pneumonia and COVID-19: A comparative, observational study. Intensive Care Med. Exp. 2021, 9, 43. [Google Scholar] [CrossRef]
- Rieder, M.; Wirth, L.; Pollmeier, L.; Jeserich, M.; Goller, I.; Baldus, N.; Schmid, B.; Busch, H.J.; Hofmann, M.; Thimme, R.; et al. Serum Protein Profiling Reveals a Specific Upregulation of the Immunomodulatory Protein Progranulin in Coronavirus Disease 2019. J. Infect. Dis. 2021, 223, 775–784. [Google Scholar] [CrossRef]
- Fonseca, W.; Asai, N.; Yagi, K.; Malinczak, C.A.; Savickas, G.; Johnson, C.C.; Murray, S.; Zoratti, E.M.; Lukacs, N.W.; Li, J.; et al. COVID-19 Modulates Inflammatory and Renal Markers That May Predict Hospital Outcomes among African American Males. Viruses 2021, 13, 2415. [Google Scholar] [CrossRef]
- Bai, G.; Furushima, D.; Niki, T.; Matsuba, T.; Maeda, Y.; Takahashi, A.; Hattori, T.; Ashino, Y. High Levels of the Cleaved Form of Galectin-9 and Osteopontin in the Plasma Are Associated with Inflammatory Markers That Reflect the Severity of COVID-19 Pneumonia. Int. J. Mol. Sci. 2021, 22, 4978. [Google Scholar] [CrossRef]
- Luis García de Guadiana, R.; Mulero, M.D.R.; Olivo, M.H.; Rojas, C.R.; Arenas, V.R.; Morales, M.G.; Abellán, A.B.; Conesa-Zamora, P.; García-García, J.; Hernández, A.C.; et al. Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: A case series. J. Infect. 2021, 82, e40–e42. [Google Scholar] [CrossRef] [PubMed]
- Alserawan, L.; Peñacoba, P.; Orozco Echevarría, S.E.; Castillo, D.; Ortiz, E.; Martínez-Martínez, L.; Moga Naranjo, E.; Domingo, P.; Castellví, I.; Juárez, C.; et al. Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics 2021, 11, 1998. [Google Scholar] [CrossRef] [PubMed]
- Moulana, Z.; Bagherzadeh, M.; Mirzakhani, M.; Rostami, A.; Mohammadnia-Afrouzi, M.; Shahbazi, M. Increased Levels of serum Pentraxin 3 in Critical Coronavirus Disease-2019 Patients. Environ. Sci. Pollut. Res. Int. 2021, 29, 85569–85573. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Barbalho, S.M.; Minniti, G.; Miola, V.F.B.; Haber, J.F.d.S.; Bueno, P.C.d.S.; de Argollo Haber, L.S.; Girio, R.S.J.; Detregiachi, C.R.P.; Dall’Antonia, C.T.; Rodrigues, V.D.; et al. Organokines in COVID-19: A Systematic Review. Cells 2023, 12, 1349. https://doi.org/10.3390/cells12101349
Barbalho SM, Minniti G, Miola VFB, Haber JFdS, Bueno PCdS, de Argollo Haber LS, Girio RSJ, Detregiachi CRP, Dall’Antonia CT, Rodrigues VD, et al. Organokines in COVID-19: A Systematic Review. Cells. 2023; 12(10):1349. https://doi.org/10.3390/cells12101349
Chicago/Turabian StyleBarbalho, Sandra Maria, Giulia Minniti, Vitor Fernando Bordin Miola, Jesselina Francisco dos Santos Haber, Patrícia Cincotto dos Santos Bueno, Luiza Santos de Argollo Haber, Raul S. J. Girio, Cláudia Rucco Penteado Detregiachi, Camila Tiveron Dall’Antonia, Victória Dogani Rodrigues, and et al. 2023. "Organokines in COVID-19: A Systematic Review" Cells 12, no. 10: 1349. https://doi.org/10.3390/cells12101349